Oraticx

Oraticx is a specialized biotechnology company based in South Korea that focuses on the research and development of oral probiotics. Originally established as OraPharm, the company leverages its expertise in the oral microbiome to develop solutions for dental health issues such as halitosis, gingivitis, and periodontitis. Their core technology centers on patented probiotic strains, most notably Weissella cibaria CMU and CMS1, which have been clinically shown to inhibit the growth of harmful oral bacteria. Oraticx operates a vertically integrated business model, encompassing strain discovery, clinical validation, and the manufacturing of both raw ingredients and finished consumer products. The company aims to lead the global oral microbiome market by providing natural, evidence-based alternatives to traditional chemical oral care.